Application of PD-L1 as drug target in screening of drugs for inhibiting tendon adhesion

The invention discloses application of PD-L1 as a drug target to screening of a drug for inhibiting tendon adhesion, and belongs to the field of biological medicine. On the basis of animal models with tendon injury of rats and chickens, PD-L1 is knocked down or PD-L1 and TGF-beta1 are knocked down in a combined mode through designed PD-L1siRNA and TGF-beta1 siRNA of the rats and the chickens, and the result shows that the extracellular matrix environment after tendon injury can be remodeled, CD8 + T cell immunological superiority can be activated, tendon adhesion formation can be effectively inhibited, and the sliding function can be effectively improved. The invention provides a potential treatment method for inhibiting the formation of tendon adhesion and improving the sliding function. 本发明公开了PD-L1作为药物靶点在筛选抑制肌腱粘连药物中的应用，属于生物医药领域。本发明以大鼠和鸡的肌腱损伤的动物模型为基础，通过设计的大鼠和鸡的PD-L1siRNA和TGF-β1siRNA，敲低PD-L1或者联合敲低PD-L1和TGF-β1，结果显示能够重塑肌腱损伤后细胞外基质环境，激活CD8+T细胞免疫优势，可以有效抑制肌腱粘连形成和改善滑动功能。本发明为抑制肌腱粘连形成和改善滑动功能提供了一种潜在的治疗方法。